의료진소개

조재철 프로필사진

혈액내과 조재철 부교수(암병원 병원장, 혈액암센터장, 분과장)

전문진료분야

림프종, 다발골수종, 만성림프구성백혈병, 혈소판질환, 빈혈, 백혈구질환, 각종 혈액질환

조재철 진료일정으로 요일별 오전, 오후 일정 제공
요일 월 화 수 목 금
오전 진료 통합진료 진료 진료
오후 진료 진료

상세정보

학력
  • 조선대학교 의과대학 의학사(2003년)
  • 울산대학교 대학원 의학석사(2008년)
  • 방송통신대학교 정보통계학과 학사(2010년)
  • 울산대학교 대학원 의학박사(2014년)
 
경력
  • 서울아산병원 인턴 (2003년)
  • 서울아산병원 내과 전공의 (2004년-2007년)
  • 내과 군의관 (2008년-2010년)
  • 서울아산병원 종양내과 임상강사 (2011년-2012년)
  • 울산대학교병원 혈액종양내과 임상조교수 (2013년)
  • 울산대학교병원 혈액종양내과 조교수 (2014년-2018년)
  • 울산대학교병원 혈액종양내과 부교수(현재)
 
논문
  1. Jo JC, Lee DH, Kang BW, Lee SS, Sym SJ, Kim MK, Ahn JH, Lee JL, Kim SW, Suh C, Kang YK, Lee JS. Both-sided intra-atrial intracardiac metastases as the initial presentation of testicular seminoma. Jpn J Clin Oncol. 2007 Jun;37(6):463-8.
  2. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008 Jan;87(1):43-8.
  3. Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, Kim TW, Lee JS, Kang YK. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol. 2007 Dec;37(12):936-41.
  4. Jo JC, Lee DH, Song HJ, Kim SW, Suh C, Kang YK. Infarction and Perforation of the Small Intestine due to Tumor Emboli from Disseminated Rectal Cancer. Gut Liver. 2008 Sep;2(2):130-2.
  5. Jo JC, Kang BW, Sym SJ, Lee SS, Jang G, Kim S, Lee DH, Kim SW, Lee JS, Suh C. Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. Invest New Drugs. 2011 Feb;29(1):175-81.
  6. Jo JC, Lee JL, Ryu MH, Chang HM, Kim M, Lee HJ, Kim HS, Shin JG, Kim TW, Kang YK. Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. Br J Cancer. 2012 May 8;106(10):1591-7.
  7. Jo JC, Yoon DH, Kim S, Jang S, Park CJ, Chi HS, Park CS, Huh J, Lee SW, Suh C.Increment of hematopoietic progenitor cell count as an indicator of efficient autologs stem cell harvest in patients with multiple myeloma. J Clin Apher. 2012 Nov;27(5):229-34.
  8. Jo JC, Yoon DH, Kim S, Lee BJ, Jang YJ, Park CS, Huh J, Lee SW, Ryu JS, Suh C. Clinical features and prognostic model for extranasal NK/T-cell lymphoma. Eur J Haematol. 2012 Aug;89(2):103-10.
  9. Ahn HK, Lee S, Park YH, Sohn JH, Jo JC, Ahn JH, Jung KH, Park S, Cho EY, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kim SB, Im YH. Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram. Neuro Oncol. 2012 Aug;14(8):1105-13.
  10. Jo JC, Yoon DH, Kim S, Park JS, Park CS, Huh J, Lee SW, Ryu JS, Suh C. Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. Korean J Hematol. 2012 Jun;47(2):119-25.
  11. Jo JC, Ryu MH, Koo DH, Ryoo BY, Kim HJ, Kim TW, Choi KD, Lee GH, Jung HY, Yook JH, Oh ST, Kim BS, Kim JH, Kang YK. Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer. Asia Pac J Clin Oncol. 2013 Dec;9(4):324-30.
  12. Jo JC, Hong YS, Kim KP, Lee JL, Kim HJ, Lee MW, Lim SB, Yu CS, Kim JC, Kim JH, Kim TW. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Eur J Dermatol. 2013 Jan-Feb;23(1):77-82.
  13. Jo JC, Kang MJ, Kim JE, Ahn JH, Jung KH, Gong G, Kim HH, Ahn SD, Kim SS, Son BH, Ahn SH, Kim SB. Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience. Cancer Chemother Pharmacol. 2013 Jul;72(1):201-7.
  14. Jo JC, Yoon DH, Kim S, Lee K, Kang EH, Jang S, Park CJ, Chi HS, Huh J, Park CS, Suh C. Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma. Ann Hematol. 2014 Mar;93(3):463-9.
  15. Jo JC, Hong YS, Kim KP, Lee JL, Lee J, Park YS, Kim SY, Ryu JS, Lee JS, Kim TW. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs. Invest New Drugs. 2014 Apr;32(2):369-76.
  16. Yoo C, Yoon DH, Jo JC, Yoon S, Kim S, Lee BJ, Huh J, Lee SW, Suh C. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. Ann Hematol. 2014 Jun;93(6):995-1000.
  17. Kim H, Lee JH, Joo YD, Bae SH, Lee JH, Kim DY, Lee WS, Ryoo HM, Jo JC, Park JH, Lee KH. Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial. Acta Haematol. 2014;132(1):87-96.
  18. Heo SK, Noh EK, Yoon DJ, Jo JC, Park JH, Kim H. Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity. PLoS One. 2014 Jun 11;9(2):e98859.
  19. Heo SK, Noh EK, Yoon DJ, Jo JC, Koh S, Baek JH, Park JH, Min YJ, Kim H. Rosmarinic acid potentiates ATRA-induced macrophage differentiation in acute promyelocytic leukemia NB4 cells. Eur J Pharmacol. 2015 Jan 15;747:36-44.
  20. Kim H, Lee WS, Lee KH, Bae SH, Kim MK, Joo YD, Zang DY, Jo JC, Lee SM, Lee JH, Lee JH, Kim DY, Ryoo HM, Hyun MS, Kim HJ; CoOperative Study Group A for Hematology (COSAH). Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. Ann Hematol. 2015 May;94(5):739-46.
  21. Choi E, Jo JC, Yoon DH, Kim S, Lee K, Huh J, Park CS, Lee SW, Suh C. Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient. Cancer Res Treat. 2015 Jul;47(3):539-43.
  22. Jo JC, Baek JH, Koh SJ, Kim H, Min YJ, Lee BU, Kim BG, Jeong ID, Cho HR, Kim GY. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea. Asia Pac J Clin Oncol. 2015 Dec;11(4):282-7.
  23. Kim H, Lee JH, Joo YD, Bae SH, Lee JH, Kim DY, Lee WS, Ryoo HM, Jo JC, Choi Y, Lee KH. CoOperative Study Group A for Hematology (COSAH). A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial. Eur J Haematol. 2016 Feb;96(2):188-97.
  24. Yhim HY, Kim JS, Mun YC, Moon JH, Chae YS, Park Y, Jo JC, Kim SJ, Yoon DH, Cheong JW, Kwak JY, Lee JJ, Kim WS, Suh C, Yang DH. Consortium for Improving Survival of Lymphoma (CISL) study. Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer/T-cell lymphoma. Biol Blood Marrow Transplant. 2015 Sep;21(9):1597-604.
  25. Heo SK, Noh EK, Yoon DJ, Jo JC, Choi Y, Koh S, Baek JH, Park JH, Min YJ, Kim H. Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells. PLoS One. 2015 Jun 12;10(6):e0129853. 3.
  26. Shin HJ, Yoon DH, Lee HS, Oh SY, Yang DH, Kang HJ, Chong SY, Park Y, Do Y, Lim SN, Jo JC, Lee WS, Chung J; Consortium for Improving Survival of Lymphoma. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B cell lymphoma patientsExp Hematol. 2016 Jan;44(1):3-13.
  27. Jo JC, Choi EK, Shin JS, Moon JH, Hong SW, Lee HR, Kim SM, Jung SA, Lee DH, Jung SH, Lee SH, Kim JE, Kim KP, Hong YS, Suh YA, Jang SJ, Choi EK, Lee JS, Jin DH, Kim TW. Targeting FGFR pathway in human hepatocellular carcinoma (HCC) expressing pFGFR and pMET for anti-tumor activity. Mol Cancer Ther. 2015 Nov;14(11):2613-22.
  28. Kim C, Lee HS, Min CK, Lee JJ, Kim K, Yoon DH, Eom HS, Lee H, Lee WS, Shin HJ, Lee JH, Park Y, Jo JC, Do YR, Mun YC. The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. Korean J Intern Med. 2015 Sep;30(5):675-83.
  29. Seo M, Kim H, Jo JC, Choi Y, Cha HJ, Lim JH, Park SH. Mass-forming extramedullary hematopoiesis in multiple myeloma: 18F-FDG PET/CT is useful in excluding extramedullary myeloma involvement. Tumori. 2015 Sep 30
  30. Jo JC, Choi Y, Shin HJ, Yhim SN, Lee HS, Lee WS, Lee JH, Kim H, Oh SY. Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). Ann Hematol. 2016 Mar;95(4):619-24.
  31. Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016 Mar;17(3):389-400.
  32. Jeong G, Kim J, Han S, Lee J, Park K, Pak C, Lim JH, Cha HJ, Kim H, Jo JC. Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report. Oncol Lett. 2016 Feb;11(2):1469-1473.
  33. Jo JC, Baek JH, Lee JH, Joo YD, Bae SH, Lee JL, Lee JH, Kim DY, Lee WS, Ryoo HM, Choi Y, Kim H, Lee KH; CoOperative Study Group A for Hematology (COSAH). Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. Asia Pac J Clin Oncol. 2016 Mar 9.
  34. Lee HS, Min CK, Lee JJ, Kim K, Kim SJ, Yoon DH, Eom HS, Lee H, Lee WS, Shin HJ, Lee JH, Park Y, Jo JC, Do YR, Mun YC, Lee MH; Korean Multiple Myeloma Working Party (KMMWP).. The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. Ann Hematol. 2016 May;95(6):911-9.
  35. Yang YJ, Seo M, Jeon HJ, Noh JH, Park SH, Choi Y, Jo JC, Baek JH, Koh SJ, Kim H, Min YJ. Metastatic prostate cancer initially presenting as chylothorax: A case report. Mol Clin Oncol. 2016 Jun;4(6):1009-1012.
  36. Kim H, Lee JH, Joo YD, Bae SH, Lee SM, Jo JC, Choi Y, Lee JH, Kim DY, Ryoo HM, Lee KH; CoOperative Study Group A for Hematology (COSAH).. Comparable Allogeneic Hematopoietic Cell Transplantation Outcome of a Haplo-Identical Family Donor with an Alternative Donor in Adult Aplastic Anemia. Acta Haematol. 2016;136(3):129-39.
  37. Park YT, Park CH, Bae MA, Jung HS, Lee YI, Lim JH, Cha HJ, Seo MJ, Park SH, Choi Y, Kim H, Jo JC. Angioimmunoblastic T-Cell Lymphoma in a Patient with Klinefelter Syndrome. Am J Case Rep. 2016 Jul 25;17:529-34.
  38. Heo SK, Noh EK, Gwon GD, Kim JY, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors. Eur J Pharmacol. 2016 Oct 15;789:280-90.
  39. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators.. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66.
  40. Jo JC, Kim M, Choi Y, Kim HJ, Kim JE, Chae SW, Kim H, Cha HJ. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2017 Jan;96(1):25-31.
  41. Seo M, Kim H, Jo JC, Choi Y, Cha HJ, Lim JH, Park SH. Mass-forming extramedullary hematopoiesis in multiple myeloma: 18F-FDG PET/CT is useful in excluding extramedullary myeloma involvement. Tumori. 2016 Nov 11;102(Suppl. 2):116-118.
  42. Heo SK, Noh EK, Gwon GD, Kim JY, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells. PLoS One. 2016 Nov 11;11(11):e0166589.
  43. Heo SK, Noh EK, Kim JY, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells. Eur J Pharmacol. 2017 Jun 5;804:52-56.
  44. Kim H, Lim YM, Jin JY, Yoon DH, Suh C, Kim SY, Jo JC, Kim KK. Electrophysiological features of POEMS syndrome compared to MGUS-related neuropathy. Muscle Nerve. 2017 May 4.
  45. Lee KH, Lee JH, Lee JH, Kim DY, Park HS, Choi EJ, Ko SH, Seol M, Lee YS, Kang YA, Jeon M, Baek S, Kang YL, Kim SH, Yun SC, Kim H, Jo JC, Choi Y, Joo YD, Lim SN. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Biol Blood Marrow Transplant. 2017 May 25.
  46. Jung SH, Lee JJ, Kim K, Suh C, Yoon DH, Min CK, Sohn SK, Choi CW, Lee HS, Kim HJ, Shin HJ, Bang SM, Yoon SS, Park SK, Yhim HY, Kim MK, Jo JC, Mun YC, Lee JH, Kim JS; Korean Multiple Myeloma Working Party. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget. 2017 Jun 16.
  47. Choi Y, Jo JC, Jeon HJ, Kim DW, Chang MH, Kim H. Trend and treatment patterns of aplastic anemia in Korea, pure red cell aplasia and myelodysplastic syndrome in Korea: a nation-wide analysis. Int J Hematol. 2017 Jun 29.
  48. Jo JC, Yoon DH, Kim S, Lee K, Kang EH, Park JS, Ryu JS, Huh J, Park CS, Kim JH, Lee SW, Suh C Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. Ann Hematol. 2017 Sep;96(9):1509-1515.
  49. Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, Lee JH, Park Y, Lee HS, Eom HS, Shin HJ, Min CK, Kim JS, Jo JC, Kang HJ, Mun YC, Lee WS, Lee JJ, Suh C, Kim K; and the Korean Multiple Myeloma Working Party. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. Am J Hematol. 2017 Aug 22.
  50.  Seo J, Kim WS, Kim JS, Kim SJ, Lee JH, Hong JS, Lee GW, Oh SY, Lee JH, Yoon DH, Lee WS, Kim HJ, Kwak JY, Kang HJ, Jo JC, Park Y, Lee HS, Kim HJ, Suh C. Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Blood Res. 2017 Sep;52(3):200-206.
  51. Jung SH, Lee JJ, Kim K, Suh C, Yoon DH, Min CK, Sohn SK, Choi CW, Lee HS, Kim HJ, Shin HJ, Bang SM, Yoon SS, Park SK, Yhim HY, Kim MK, Jo JC, Mun YC, Lee JH, Kim JS; Korean Multiple Myeloma Working Party. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget. 2017 Jun 16;8(45):79517-79526.
  52. Heo SK, Noh EK, Kim JY, Jeong YK, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Sci Rep. 2017 Nov 10;7(1):15278.
  53. Hong JY, Yoon DH, Suh C, Kim WS, Kim SJ, Jo JC, Kim JS, Lee WS, Oh SY, Park Y, Kim SY, Lee MH, Lee HS, Do YR. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. Ann Hematol. 2018 Aug;97(8):1437-1443.
  54. Heo SK, Noh EK, Kim JY, Jegal S, Jeong Y, Cheon J, Koh S, Baek JH, Min YJ, Choi Y, Jo JC. Rhein augments ATRA-induced differentiation of acute promyelocytic leukemia cells. Phytomedicine. 2018 Oct 1;49:66-74.
  55. Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-2087.
  56. Shin J, Lee JJ, Kim K, Min CK, Lee JO, Suh C, Kim JS, Lee YJ, Yoon SS, Jo JC, Lee HS, Bang SM; Korean Multiple Myeloma 151 Investigators. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. Int J Hematol. 2019 Jan;109(1):79-90.
  57. Lee IH, Kang BW, Kim JG, Bae WK, Ki MS, Park I, Jo JC, Kim JY, Koh SA, Lee KH, Cho YY, Ryoo HM, Kwak SG, Lee JL, Lee SA. Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy. Korean J Intern Med. 2018 Oct 12.
  58. Kim J, Lim JH, Jeong J, Lee SH, Jo JC, Park SH. Low-grade follicular lymphoma involvement of the bone marrow with a mixed paratrabecular, diffuse, and massive pattern expressing typical mantle cell lymphoma immunophenotype CD23-/FMC7+: a case report. Blood Res. 2018 Sep;53(3):261-263.
  59. Park SH, Jeong J, Lee SH, Yoo DW, Choi Y, Jo JC, Lim JH. Comparison of High Sensitivity and Conventional Flow Cytometry for Diagnosing Overt Paroxysmal Nocturnal Hemoglobinuria and Detecting Minor Paroxysmal Nocturnal Hemoglobinuria Clones. Ann Lab Med. 2019 Mar;39(2):150-157.
  60. Seo M, Ha ND, Jo JC, Park SH. Chronic Vasitis After Mesh Herniorrhaphy: A Potential Cause of False Positive Results in 18F-FDG PET/CT Studies. Clin Nucl Med. 2019 Feb;44(2):e104-e106.
  61. Park S, Jo JC, Do YR, Yang DH, Lim SN, Lee WS, Kim WS, Lee HS, Hong DS, Kim HJ, Shin HJ. Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):149-156.
  62. Park LC, Song YJ, Kim DJ, Kim MJ, Jo JC, Lee WS, Shin HJ, Oh SY, Do YR, Jeong JY, Lee HS; Consortium for Improving Survival of Lymphoma (CISL). The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients. Int J Cancer. 2019 Nov 1;145(9):2459-2467.
  63. Heo SK, Noh EK, Jeong YK, Ju LJ, Sung JY, Yu HM, Cheon J, Koh S, Min YJ, Choi Y, Jo JC. Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression. Tumour Biol. 2019 May;41(5): 1-13
  64. Park BB, Kim WS, Suh C, Hong JY, Yang DH, Lee WS, Do YR, Koh YI, Won JH, Kim MK, Jo JC, Hyun SY, Kim JA, Oh YH, Lee SS. A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). Leuk Lymphoma. 2019 Jun 6:1-7.
  65. Huh SJ, Oh SY, Lee S, Lee JH, Kim SH, Lee GW, Kim SJ, Kim WS, Lee HS, Jo JC, Kim MJ, Kwon JH, Kim HJ. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. Int J Hematol. 2019 Oct;110(4):438-446.
  66. Seo M, Cha HJ, Kim M, Park SH, Lim JH, Choi Y, Lee YJ, Park SH, Jo JC. Clinical Utility of 18F-Florbetaben PET for Detecting Amyloidosis Associated With Multiple Myeloma: A Prospective Case-Control Study. Clin Nucl Med. 2019 Sep;44(9):e503-e509.
  67. Lee YJ, Moon JH, Sohn SK, Kim SJ, Jung SH, Lee JJ, Jo JC, Shin HJ, Lee WS, Lee JH, Bae SH, Kim MK, Lee HS, Kim K, Min CK; Korean Multiple Myeloma Working Party. Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2019 Dec;54(12):2051-2059.
  68. Yi JH, Lee GW, Do YR, Jung HR, Hong JY, Yoon DH, Suh C, Choi YS, Yi SY, Sohn BS, Kim BS, Oh SY, Park J, Jo JC, Lee SS, Oh YH, Kim SJ, Kim WS. Yi JH, Lee GW, Do YR, Jung HR, Hong JY, Yoon DH, Suh C, Choi YS, Yi SY, Sohn BS, Kim BS, Oh SY, Park J, Jo JC, Lee SS, Oh YH, Kim SJ, Kim WS. Ann Hematol. 2019 Nov;98(11):2541-2550.
  69. Park SH, Kim J, Jeong J, Lee SH, Cha HJ, Park SH, Choi Y, Jo JC, Lim JH. High-grade nodal marginal zone lymphoma with diffuse bone marrow involvement and IgM-type monoclonal paraproteinemia: a case report and review of the literature. Blood Res. 2019 Sep;54(3):229-231.
  70. Park SH, Lim JH, Jeong J, Lee SH, Cha HJ, Choi Y, Jo JC. Bone marrow metastasis of small cell lung carcinoma with spontaneous tumor lysis syndrome without hepatic metastasis at diagnosis: first case report in Korea and review of literature. Blood Res. 2019 Sep;54(3):231-233.
  71. Park SH, Jeong J, Lee SH, Choi Y, Jo JC, Lim JH. Distinct Clinical Features of Plasma Cell Myeloma Patients Exhibiting Dysmorphic Plasma Cells: Association with More Plasma Cells at Diagnosis. Indian J Hematol Blood Transfus. 2019 Oct;35(4):662-672.
  72. Jo JC, Kim SJ, Lee HS, Eom HS, Lee SI, Park Y, Lee JO, Lee Y, Yhim HY, Yang DH, Byun JM, Kang HJ, Kim HJ, Shin HJ, Yoo KH, Suh C; and Consortium for Improving Survival of Lymphoma (CISL). Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. Ann Hematol. 2020 Feb;99(2):223-228.
  73. Jo JC, Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Cho SH, Park SK, Yi JH, Lee JH, Kim J, Min CK; Korean Multiple Myeloma Working Party (KMMWP). The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). Ann Hematol. 2020 Feb;99(2):309-319.
  74. Hong JY, Yoon DH, Yoon SE, Kim SJ, Lee HS, Eom HS, Lee HW, Shin DY, Koh Y, Yoon SS, Jo JC, Kim JS, Kim SJ, Cho SH, Lee WS, Won JH, Kim WS, Suh C. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. Sci Rep. 2019 Dec 30;9(1):20302.
  75. Won YW, Lee H, Eom HS, Kim JS, Suh C, Yoon DH, Hong JY, Kang HJ, Lee JH, Kim WS, Kim SJ, Lee WS, Chang MH, Do YR, Yi JH, Kim I, Won JH, Kim K, Oh SY, Jo JC. A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. Ann Hematol. 2020 Feb;99(2):255-264.
  76. Kim DJ, Kim T, Jeong JY, Jo JC, Lee WS, Shin HJ, Lee JH, Lee HS. Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma. Int J Hematol. 2020 Apr;111(4):559-566.
  77. Kim DY, Chung JS, Jo JC, Cho SH, Shin HJ. Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma. Ann Hematol. 2020 Apr;99(4):819-828.
  78. Sook-Kyoung Heo, Eui-Kyu Noh, Lan Jeong Ju, Jun Young Sung, Yoo Kyung Jeong, Jaekyung Cheon, SuJin Koh, Young Joo Min, Yunsuk Choi, Jae-Cheol Jo. CD45dimCD34+CD38-CD133+ cells have the potential as leukemic stem cells in acute myeloid leukemia. BMC cancer 2020 Apr 6;20(1):285.
  79. Choi Y, Lee JH, Jung CW, Jo JC, Kim JS, Kim I, Park S, Cheong JW, Park SH, Kim SY, Lee HG. Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. Korean J Intern Med. 2020 Apr 14.
  80. Jo JC, Kim JS, Lee JH, Lee JH, Lim SN, Lee SM, Yoon SS, Kim IH, Bae SH, Lee YJ, Choi Y, Lee WS. Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). Bone Marrow Transplant. 2020 Apr 17.
  81. Choi Y, Lee JH, Lee JH, Park HS, Choi EJ, Jo JC, Lee YJ, Lee YS, Kang YA, Lee KH. Title: Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Eur J Haematol. 2020 Apr 30.
82. Jung J, Choi YS, Lee JH, Lee WS, Kim SH, Park Y, Lee SS, Do YR, Jo JC, Lee JJ, Kim JS, Shin HJ, Shin DY, Yoon SS, Min CK, Kim K, Eom HS; Korean Multiple Myeloma Working Party (KMMWP). Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. Int J Hematol. 2020 Jul;112(1):84-95.
83. Cheon J, Lee YJ, Jo JC, Kweon K, Koh S, Min YJ, Park SH, Lee SH, Kim HJ, Choi Y. Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation Support Care Cancer. 2020 Jun 17.
84. Lee KW, Chung IJ, Ryu MH, Park YI, Nam BH, Oh HS, Lee KH, Han HS, Seo BG, Jo JC, Lee HR, Kim JW, Park SR, Cho SH, Kang YK; SOPP study investigators. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer. 2020 Jun 28.
85. Jung SH, Jo JC, Song GY, Ahn SY, Yang DH, Ahn JS, Kim HJ, Lee JJ. Frontline therapy for newly diagnosed patients with multiple myeloma Blood Res. 2020 Jul 31;55(S1):S37-S42.
86. Jeong S, Park YJ, Yun W, Lee ST, Choi JR, Suh C, Jo JC, Cha HJ, Jeong JY, Chang H, Cha YJ, Kim H, Park MJ, Song W, Cho EH, Jeong EG, Lee J, Park Y, Lee YS, Kim DJ, Lee HS. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study Sci Rep. 2020 Aug 7;10(1):13359.
87. Weisel K, Spencer A, Lentzsch S, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka A, Quach H, Munder M, Lee C, Barreto W, Corradini P, Min CK, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Casneuf T, DeAngelis N, Amin H, Ukropec J, Kobos R, Mateos MV. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk J Hematol Oncol. 2020 Aug 20;13(1):115.
88. Heo SK, Noh EK, Yu HM, Kim DK, Seo HJ, Lee YJ, Cheon J, Koh SJ, Min YJ, Choi Y, Jo JC. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death. BMC Cancer. 2020 Dec 4;20(1):1193
89. Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Jo JC, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Park SK, Yi JH, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP). Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone Int J Hematol. 2021 Jan;113(1):81-91.
90. Jo JC, Kim JS, Lee JH, Lee JH, Im SN, Lee SM, Yoon SS, Kim IH, Bae SH, Lee YJ, Choi Y, Lee WS. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas Ann Hematol
. 2021 Jan;100(1):189-196.
91. Choi Y, Choi EJ, Lee JH, Lee KH, Jo JC, Park HS, Lee YJ, Seol M, Lee YS, Kang YA, Jeon M, Lee JH. Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation Clin Transplant. 2021 Mar;35(3):e14199.
92. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial Ann Hematol. 2021 Aug;100(8):2051-2059. Lee JH, Park Y, Kang KW, Lee JJ, Lee HS, Eom HS, Do YR, Kim JS, Yoon SS, Shin DY, Koh Y, Kim KH, Lee WS, Jo JC, Lee YJ, Lee JY, Kim DS, Shim H, Chang MH, Kim SH, Min CK; Korean multiple myeloma working party [KMMWP].
93. Heo SK, Choi Y, Jeong YK, Ju LJ, Yu HM, Kim DK, Seo HJ, Lee YJ, Cheon J, Koh S, Min YJ, Noh EK, Jo JC. LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells PLoS One. 2021 Feb 19;16(2):e0247368.
94. Yi JH, Kim SJ, Yoon DH, Suh C, Chang MH, Yang DH, Jo JC, Hyun SY, Eom HS, Lee JO, Kwon JH, Han SH, Lee SS, Kwak JY, Kim SH, Kim DS, Lee JH, Oh SY, Ryoo HM, Kim HJ, Kim WS. Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis Cancer Commun (Lond). 2021 Mar;41(3):275-278.
95. Cheon J, Im HS, Shin HJ, Kim I, Lee WS, Lee KH, Park SK, Kim MK, Choi UJ, Kim JH, Lee I, Jo JC. Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea Support Care Cancer. 2021 Sep;29(9):5383-5390.
96. Kim H, Im HS, Lee KO, Min YJ, Jo JC, Choi Y, Lee YJ, Kang D, Kim C, Koh SJ, Cheon J. Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act BMC Palliat Care. 2021 Apr 27;20(1):63.
97. Heo SK, Noh EK, Kim JY, Yu HM, Sung JY, Ju LJ, Kim DK, Seo HJ, Lee YJ, Cheon J, Koh S, Min YJ, Choi Y, Jo JC. The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway Sci Rep. 2021 Jun 24;11(1):13198.
98. Lee YP, Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh YI, Kang KW, Lee HS, Wei KTK, Lim ST, Poon M, Irawan C, Zhao W, Do YR, Lee MH, Ng SC, Lee WS, Guo Y, Zhang H, Kang HJ, Yun HJ, Kim HJ, Lung DTC, Kwak JY, Han JJ, Mun YC, Oh SY, Shim H, Kwon JH, Sohn BS, Park SK, Jo JC, Ko YH, Jun Z, Kim WS. Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia Int J Hematol. 2021 Sep;114(3):355-362.
99. Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh Y, Kang KW, Lee HS, Tay KKW, Lim ST, Poon M, Irawan C, Zhao W, Do YR, Lee MH, Ng SC, Lee WS, Guo Y, Zhang H, Kang HJ, Yun HJ, Kim HJ, Lung DTC, Kwak JY, Han JJ, Mun YC, Oh SY, Shim H, Kwon JH, Sohn BS, Park SK, Jo JC, Ko YH, Jun Z, Kim WS. Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia Lancet Reg Health West Pac. 2021 Mar 22;10:100126.
100. Lee HS, Lee J, Jo JC, Jung SH, Lee JJ, Kim D, Lee S, Song K. Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population Sci Rep. 2021 Nov 25;11(1):22907.
101. Cho HJ, Jung SH, Jo JC, Lee YJ, Yoon SE, Park SS, Kim DY, Shin HJ, Mun YC, Yi JH, Kim HJ, Kim DJ, Lee HS, Bae SH, Hong CM, Jeong SY, Min JJ, Sohn SK, Min CK, Kim K, Lee JJ, Moon JH; Korean Multiple Myeloma Working Party. Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18 F-FDG PET/CT Blood Cancer J. 2021 Dec 1;11(12):190.
  1. 102. Kim DY, Nam J, Chung JS, Jeon BE, Lee JH, Jo JC, Kim SW, Shin HJ. Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia During R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma Cancer Res Treat. 2021 Dec 31.
  1. 103. Jeong SH, Kim SJ, Yoon DH, Park Y, Kang HJ, Koh Y, Lee GW, Lee WS, Yang DH, Do YR, Kim MK, Yoo KH, Choi YS, Yun HJ, Yi JH, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Hyun SY, Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Kim SH, Lee HS, Suh C, Kim WS. Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study Cancer Res Treat. 2021 Dec 30.
  1. 104. Kim SI, Jung SH, Yhim HY, Jo JC, Song GY, Kim M, Ahn SY, Ahn JS, Yang DH, Kim HJ, Lee JJ. Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen Blood Res. 2022 Mar 31;57(1):51-58.
  1. 105. Yi JH, Jeong SH, Kim SJ, Yoon DH, Kang HJ, Koh Y, Kim JS, Lee WS, Yang DH, Do YR, Kim MK, Yoo KH, Choi YS, Yun WJ, Park Y, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Hong DS, Lee HS, Lee GW, Suh C, Kim WS. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. Cancer Res Treat. 2022 Apr 22.
  1. 106. Heo SK, Noh EK, Seo HJ, Lee YJ, Koh S, Min YJ, Choi Y, Jo JC. Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling. PLoS One. 2022 May 3;17(5):e0265958.
  1. 107. Choi S, Seo M, Park SH, Jo JC, Chae SW, Lee JH, Cha HJ. Clinicopathologic Characteristics Associated with Prognosis in Ocular Extranodal Marginal Zone B Cell Lymphoma. Medicina (Kaunas). 2022 Jun 17;58(6):818.
  2. 108. Heo SK, Noh EK, Lee YJ, Shin Y, Kim Y, Im HS, Kim H, Koh SJ, Min YJ, Jo JC, Choi Y. The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation BMC Cancer. 2022 Sep 20;22(1):997.
    109. Choi S, Lee YJ, Choi Y, Kim M, Kim HJ, Kim JE, Oh S, Chae SW, Cha HJ, Jo JC. Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma J Pathol Transl Med. 2022 Sep;56(5):281-288.
    110. Seo KI, Jo JC, Kim DJ, Jeong JY, Lee S, Lee HS. Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma Viruses. 2022 Aug 31;14(9):1943.
    111. Lee JH, Kim SH, Kim HR, Min CK, Lee JJ, Shin HJ, Jo JC, Lee JY, Moon JH, Kim K. Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma Int J Hematol. 2023 Feb;117(2):225-235.
    112. Yi JH, Kim SJ, Lee JO, Lee GW, Kwak JY, Eom HS, Jo JC, Choi YS, Oh SY, Kim WS. Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis Anticancer Res. 2022 Dec;42(12):6083-6089.
    113. Cho H, Yoon DH, Shin DY, Koh Y, Yoon SS, Kim SJ, Do YR, Lee GW, Kwak JY, Park Y, Kim MK, Kang HJ, Yi JH, Yoo KH, Lee WS, Park BB, Jo JC, Eom HS, Kim HJ, Jeong SH, Won YW, Sohn BS, Kwon JH, Suh C, Kim WS. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404) Cancer Res Treat. 2023 Jan 2.
    114. Cho HJ, Jo JC, Lee YJ, Lee MW, Kim DY, Shin HJ, Im SN, Lee JH, Bae SH, Do YR, Lee WS, Kim MK, Jung J, Lee JM, Kim JH, Baek DW, Sohn SK, Moon JH. Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma. Korean J Intern Med. 2023 Jan 26.
    115. Kim DY, Kim YR, Suh C, Yoon DH, Yang DH, Park Y, Eom HS, Lee JO, Kwak JY, Kang HJ, Hyun SY, Jo JC, Chang MH, Yoo KH, Lim SN, Shin HJ, Kim WS, Kim IH, Kim MK, Kim HJ, Lee WS, Mun YC, Kim JS. A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Am J Gastroenterol. 2023 Feb 3
    116. Jo JC, Jean Y, Kim D, Yang DH, Lee WS, Choi YS, Yi JH, Yoon DH, Kong JH, Choe JY, Kim S, Ahn K, Park T, Ju H, Kwon S, Cho SG. A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea. Expert Opin Biol Ther. 2023 Feb 9.
    117. Jung EH, Byun JM, Shin DY, Do YR, Jo JC, Lee SM, Yoon SS. Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122) Cancer Med. 2023 Apr;12(8):9186-9193.
    118. Park SH, Lee YJ, Kim Y, Kim HK, Lim JH, Jo JC. T-large granular lymphocytic leukemia. Blood Res. 2023 Apr 30;58(S1):S52-S57.
    119. Park SH, Kim HK, Jeong J, Lee SH, Lee YJ, Kim YJ, Jo JC, Lim JH. Performance Validation of Three Scoring Systems for the Prediction of Thrombotic Microangiopathy Due to Severe ADAMTS13 Deficiency and the Response to Therapeutic Plasma Exchange: First Study in Korea Ann Lab Med. 2023 Sep 1;43(5):485-492.
    120. Lee YJ, Kim Y, Park SH, Jo JC. Plasmacytoid dendritic cell neoplasms. Blood Res. 2023 Apr 30;58(S1):90-95.
    121. Cho HJ, Jo JC, Lee YJ, Lee MW, Kim DY, Shin HJ, Im SN, Lee JH, Bae SH, Do YR, Lee WS, Kim MK, Jung J, Lee JM, Kim JH, Baek DW, Sohn SK, Moon JH. Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma Korean J Intern Med 2023 Jul;38(4):578.
    122. Lee YJ, Kim JS, Jo JC, Kim Y, Im HS, Kim H, Koh S, Min YJ, Park SH, Ahn JW, Choi Y. Risk factors of menopause after allogeneic hematopoietic cell transplantation in premenopausal adult women Eur J Haematol. 2023 Sep;111(3):449-457.
    123. Seo M, Lee YJ, Choi HJ, Jo JC, Park SH. A Case of Adenomyosis Showing Size Reduction in a Follicular Lymphoma Patient Receiving Chemotherapy With R-Bendamustine Clin Nucl Med. 2023 Sep 1;48(9):e438-e440.
    124. Baek DW, Moon JH, Lee JH, Kang KW, Lee HS, Eom HS, Lee E, Lee JH, Lee JO, Park SK, Kim SJ, Yoo KH, Yoon SS, Koh Y, Kang HJ, Won JH, Lyu CJ, Hahn SM, Lee JH, Park JS, Jo JC, Mun YC, Yang DH, Song GY, Lim SN, Sohn SK; Korean Society of Blood and Marrow Transplantation. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation Blood Cancer J. 2023 Jun 26;13(1):95.
    125. Kim M, Lee JJ, Min CK, Lee JY, Jo JC, Yoon SS, Lim SN, Do YR, Kim K, Lee JH, Yoo KH, Bae SH, Yi JH, Jung J, Eom HS, Jung SH. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015) Ann Hematol. 2023 Aug;102(8):2233-2240.
    126. Heo SK, Yu HM, Kim DK, Seo HJ, Shin Y, Kim SA, Kim M, Kim Y, Lee YJ, Noh EK, Jo JC. LIGHT (TNFSF14) promotes the differentiation of human bone marrow-derived mesenchymal stem cells into functional hepatocyte-like cells. PLoS One. 2023 Aug 8;18(8):e0289798.
    127. Kim SJ, Jo JC, Yoon DH, Yang DH, Yoon SE, Lee GW, Kong JH, Park Y, Kang KW, Lee HS, Oh SY, Shin HJ, Lee WS, Choi YS, Jeong SH, Kim MK, Kang HJ, Yi JH, Lim SN, Yhim HY, Do YR, Yun HJ, Eom HS, Lee MH, Suh C, Kim WS. Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation. Front Oncol. 2023 Aug 22;13:1230629.
    128. Lee JY, Kwon JH, Hur JY, Yi JH, Lee JH, Cho H, Do YR, Jo JC, Kang HJ, Koh Y, Lee WS, Lim SN, Yoon SE, Kim SJ, Lee JO. Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea. Cancer Res Treat. 2024 Apr;56(2):681-687.
    129. Lee HJ, Sin C, Kim H, Im HS, Jo JC, Lee YJ, Kim Y, Ahn J, Yoo S, Koh SJ, Chung S. Catastrophizing Maladaptive Coping Affects the Association Between Viral Anxiety and Fear of Progression in Cancer Patients During COVID-19 Pandemic. Psychiatry Investig. 2023 Dec;20(12):1204-1210.
    130. Kim SJ, Do YR, Lee HS, Lee WS, Kong JH, Kwak JY, Eom HS, Moon JH, Yi JH, Lee JO, Jo JC, Yang DH. A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study. Blood Res. 2023 Dec 31;58(4):194-200.
    131. Zhang Y, Patel RP, Kim KH, Cho H, Jo JC, Jeong SH, Oh SY, Choi YS, Kim SH, Lee JH, Angelos M, Guruprasad P, Cohen I, Ugwuanyi O, Lee YG, Pajarillo R, Cho JH, Carturan A, Paruzzo L, Ghilardi G, Wang M, Kim S, Kim SM, Lee HJ, Park JH, Cui L, Lee TB, Hwang IS, Lee YH, Lee YJ, Porazzi P, Liu D, Lee Y, Kim JH, Lee JS, Yoon DH, Chung J, Ruella M. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study. Mol Cancer. 2023 Dec 9;22(1):200.
    132 Park SH, Kim HK, Jeong J, Lee SH, Lee YJ, Kim YJ, Jo JC, Lim JH. Research use only and cell population data items obtained from the Beckman Coulter DxH800 automated hematology analyzer are useful in discriminating MDS patients from those with cytopenia without MDS. J Hematop. 2023 Sep;16(3):143-154.
    133. Shin HJ, Kim DY, Kim K, Min CK, Lee JJ, Mun YC, Lee WS, Lim SN, Kim JS, Moo JH, Kim DJ, Bang SM, Won JH, Jo JC, Koh YI. Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913). Cancer Res Treat. 2024 Mar 4.